Literature DB >> 8353035

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.

M Santoro1, N Sabino, Y Ishizaka, T Ushijima, F Carlomagno, A Cerrato, M Grieco, C Battaglia, M L Martelli, C Paulin.   

Abstract

Non-thyroid neoplasia were analysed by Southern blot of genomic DNA and DNA prepared by reverse transcription and amplification by polymerase chain reaction (RT/PCR) for the activation of the RET oncogene. It is known that the rearrangement of RET occurs in about 10%-20% of human thyroid papillary carcinomas. None of 528 non-thyroid tumours showed rearrangement of the RET proto-oncogene, whereas three out of 30 thyroid papillary carcinomas were positive for RET activation. Therefore the activation of RET seems to be a somatic cell mutation specific to human thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353035      PMCID: PMC1968385          DOI: 10.1038/bjc.1993.370

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

Authors:  I Bongarzone; N Monzini; M G Borrello; C Carcano; G Ferraresi; E Arighi; P Mondellini; G Della Porta; M A Pierotti
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

2.  Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line.

Authors:  T Tahira; Y Ishizaka; F Itoh; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1990-01       Impact factor: 9.867

3.  The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene.

Authors:  T I Bonner; H Oppermann; P Seeburg; S B Kerby; M A Gunnell; A C Young; U R Rapp
Journal:  Nucleic Acids Res       Date:  1986-01-24       Impact factor: 16.971

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Activation of the ret-II oncogene without a sequence encoding a transmembrane domain and transforming activity of two ret-II oncogene products differing in carboxy-termini due to alternative splicing.

Authors:  Y Ishizaka; M Ochiai; T Tahira; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

6.  [ret gene from a human stomach cancer].

Authors:  T Koda
Journal:  Hokkaido Igaku Zasshi       Date:  1988-11

7.  One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes.

Authors:  A Fusco; M T Berlingieri; P P Di Fiore; G Portella; M Grieco; G Vecchio
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

8.  Culture of hormone-dependent functional epithelial cells from rat thyroids.

Authors:  F S Ambesi-Impiombato; L A Parks; H G Coon
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

9.  PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.

Authors:  M Grieco; M Santoro; M T Berlingieri; R M Melillo; R Donghi; I Bongarzone; M A Pierotti; G Della Porta; A Fusco; G Vecchio
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

10.  High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.

Authors:  I Bongarzone; M A Pierotti; N Monzini; P Mondellini; G Manenti; R Donghi; S Pilotti; M Grieco; M Santoro; A Fusco
Journal:  Oncogene       Date:  1989-12       Impact factor: 9.867

View more
  14 in total

1.  Nuclear envelope irregularity is induced by RET/PTC during interphase.

Authors:  Andrew H Fischer; Panya Taysavang; Sissy M Jhiang
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 2.  The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.

Authors:  T Kusafuka; P Puri
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

3.  Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis?

Authors:  D G P N Villagelin; R B Santos; J H Romaldini
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

4.  High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas.

Authors:  I Martínez; A Mantilla; M E Medrano; R Hernández; D M Hernández; M Lazos; H Santiago; B González; A Hidalgo; M Salcedo
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 5.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

Review 6.  Molecular pathobiology of thyroid neoplasms.

Authors:  Giovanni Tallini
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

7.  Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer.

Authors:  Alfredo Fusco; Gennaro Chiappetta; Pei Hui; Ginesa Garcia-Rostan; Lauren Golden; Barbara K Kinder; Deborah A Dillon; Ada Giuliano; Anna Maria Cirafici; Massimo Santoro; Juan Rosai; Giovanni Tallini
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 8.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure.

Authors:  A H Fischer; J A Bond; P Taysavang; O E Battles; D Wynford-Thomas
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  Recent advances in molecular diagnosis of thyroid cancer.

Authors:  Ioannis Legakis; Konstantinos Syrigos
Journal:  J Thyroid Res       Date:  2011-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.